Oncology

FDA Alert: Efficacy Concerns with Atezolizumab Plus Paclitaxel for Breast Cancer

September 11, 2020

The FDA issued a safety alert about efficacy and potential safety concerns with a combination therapy being studied for the treatment of breast cancer.

Oncology Pharmacists Adapt to Serve Patients Amid Pandemic

September 10, 2020

Oncology pharmacists have implemented new ways to communicate with patients, schedule visits and treatments, and re-evaluate their medications regimens during the pandemic.

Study: No Link Between Antihypertensive Medications and Cancer Risk

September 03, 2020

There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to a major new study.

FDA OKs Azacitidine Tablets for Acute Myeloid Leukemia

September 03, 2020

Oral azacitidine (Onureg; Celgene) is approved for patients in first remission with acute myeloid leukeimia.

Report: Specialty, Pediatric Drug Prices Projected to Rise Amid Pandemic

August 19, 2020

Oncology medical and infusion services have declined since the start of COVID-19.

Study Shows Promising Results for Olaparib and Durvalumab Combination Therapy for Certain Metastatic Breast Cancers

August 13, 2020

Results from the study showed antitumor activity and safety to be similar to olaparib and durvalumab monotherapy study findings.

Communicating Facts Can Help Boost HPV Vaccination Rates

August 12, 2020

Pharmacists should counsel patients on how taking steps now can prevent certain cancers later.

Study Compares Cost, Accessibility of Novel Cancer Drugs in US and India

August 07, 2020

The advent of generic and biosimilar medicines for novel treatments has helped bridge the gap in the delivery of cancer care between the United States and India, according to the study.

Expert Panel Updates Guidelines for Anti-Cancer Treatment Amid COVID-19

August 06, 2020

ESMO released changes to its recommendations on how to manage patients with cancer during the COVID-19 pandemic.

Study Shows Significant Decline in Cancer Screenings Amid Pandemic

August 03, 2020

A recent study evaluated the effects of the COVID-19 pandemic on normal cancer care activities, including cancer screening efforts.

FDA Accepts Supplemental New Drug Application for Selinexor as Multiple Myeloma Treatment

July 21, 2020

Karyopharm announced that the agency has accepted for filing its supplemental New Drug Application for selinexor as a second-line treatment for multiple myeloma.

Chemotherapy Stewardship Programs Needed for Cutting Cancer Costs

July 15, 2020

A recent study found that the programs may result in cost savings to health systems and patients.

FDA Approves New Combo Breast Cancer Treatment for Subcutaneous Injection

July 01, 2020

The fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase (Phesgo; Genentech) can be administered subcutaneously for patients with HER2-positive breast cancer.

Pharmacists: Fight Racial Disparities in Health Care

June 26, 2020

Today, pharmacists are banding together to “eliminate racism, discrimination, injustice, and the marginalization of individuals within the profession.”

Ribociclib Shows Overall Survival Benefit in Patients With Advanced Breast Cancer With Visceral Metastases

June 11, 2020

An exploratory analysis of 2 phase 3 trials evaluating ribociclib (Kisqali, Novartis) plus endocrine therapy in advanced breast cancer showed positive results.

Survey: Oncology Pharmacists Report Impaired Access to PPE, Certain Medications

June 10, 2020

Oncology pharmacy practitioners highlight challenges amid the pandemic, such as limited access to personal protective equipment and essential medications.

Cabozantinib With Nivolumab Extended PFS in Patients With Advanced Recurring Endometrial Cancer

June 08, 2020

The study, presented at the virtual ASCO20, showed significant clinical benefit for patients with endometrial cancer who were treated with cabozantinib and nivolumab.

FDA OKs Atezolizumab Plus Bevacizumab for Frontline Treatment of Advanced Liver Cancer

June 01, 2020

Officials with the FDA approved atezolizumab (Tecentriq, Genentech) in combination with bevacizumab (Avastin) for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Systematic Review Evaluates Cannabis, Cannabinoids in Palliative and Supportive Oncology Care

May 30, 2020

A systematic review of medical cannabis and cannabinoid use in oncology care demonstrated varied results. 

Adjuvant Osimertinib Therapy Delays Disease Recurrence in Localized NSCLC

May 30, 2020

Targeted therapy osimertinib (Tagrisso) demonstrated significant improvements in disease-free survival in patients with localized non-small cell lung cancer (NSCLC) who were treated following surgery.